EXPLORE!

FDA: Amlodipine/Valsartan recalled for possible cancer risk

  1660 Views

Dr KK Aggarwal    10 December 2018

WASHINGTON —Teva Pharmaceuticals has voluntarily withdrawn all lots of Amlodipine/Valsartan combination tablets and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets due to an impurity detected above specification limits in an active ingredient manufactured by Mylan India. The impurity is N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.

Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US.

In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs

Mylan India is a part of Mylan Inc. U.S one of the world’s leading generic and specialty pharmaceutical companies. In India we have strong manufacturing base with Active Pharmaceutical Ingredients, Oral Solid Dosage and Injectable units spread across the country. The company also has exceptional R&D facilities and fast growing commercial operations in India. Mylan India comprises of nearly 50% of Mylan Inc.’s total global workforce.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.